#### 23 February 2023 Update | Sector: Specialty Chemicals

# **Deepak Nitrite**

#### **BSE SENSEX**

59,606

INSEX

6



Motilal Oswal

S&P CNX

17,511

#### Stock Info

Bloomberg	DN IN
Equity Shares (m)	136
M.Cap.(INRb)/(USDb)	244 / 2.9
52-Week Range (INR)	2390 / 1682
1, 6, 12 Rel. Per (%)	-2/-10/-14
12M Avg Val (INR M)	1565
Free float (%)	54.3


### Financials Snapshot (INR b)

Y/E March	FY23E	FY24E	FY25E		
Sales	80.3	85.9	94.1		
EBITDA	12.6	18.4	19.9		
PAT	8.3	12.2	13.1		
EPS (INR)	60.7	89.3	96.3		
EPS Gr. (%)	(22.4)	47.2	7.7		
BV/Sh.(INR)	296.3	372.3	454.1		
Ratios					
Net D:E	0.1	(0.0)	(0.1)		
RoE (%)	22.4	26.7	23.3		
RoCE (%)	20.4	24.9	22.6		
Payout (%)	15.0	15.0	15.0		
Valuations					
P/E (x)	29.7	20.2	18.8		
P/BV (x)	6.1	4.8	4.0		
EV/EBITDA (x)	19.8	13.3	12.0		
Div. Yield (%)	0.5	0.7	0.8		
FCF Yield (%)	0.2	2.6	3.9		
Chanak aldina m					

#### Shareholding pattern (%)

45.7 13.8	45.7 12.0	45.7 10.7
13.8	12.0	107
10.0	12.0	10.7
8.7	8.5	8.8
31.8	33.8	34.7
	0	0.0

## FII Includes depository receipts



# CMP: INR1,789 TP: INR1,890 (+6%)

Neutral

# Headwinds to persist as new capacities are added

- The phenol/acetone spread over raw materials has declined 16% YoY to INR90/kg during 2HFY23 till date (v/s INR107/kg in 2HFY22) on account of China's Covid-related lockdowns, which resulted in stockpiling of Phenol and disruption in trade activities.
- China's steps toward self- sufficiency in phenol and increased competition in the region could result in a structural glut in the overall market, in turn leading to the downtrend in phenol margins to continue.
- DN's planned capex of INR15b in FY23-24 aimed partly for backward integration and partly towards downstream products of Acetone (MIBK/MIBC) should drive growth in the near term. Moreover, the recently announced INR10b expansion into Polycarbonate compounding & Nitrite project in Oman would drive growth in the medium term.
- Although the company has aggressive growth plans, the commodity nature of its products does not leave much upside for investors. If it forays into specialty products or complex commodities, it would certainly command a better valuation multiple. We reiterate our Neutral recommendation with a target price of INR1,890.

## Phenolic division margins expected to remain under pressure

- EBIT margins of DN's phenolic segment slipped to 8% in 2QFY23, the lowest level since 4QFY20. While margins improved sequentially to 11% in 3QFY23, they remain below the long term average of INR96/kg. With the phenol/acetone spread remaining flat QoQ at ~INR90/kg in 4QFY23 till date, margins are also expected to remain subdued.
- According to World Integrated Trade Solution (WITS), China is the single largest importer of phenol globally and accounted for ~52% of the top ten global phenol importing countries in CY20. With China moving toward selfsufficiency through capacity additions supported by increased feedstock availability (benzene & propylene) due to Beijing refinery restructuring, phenol realizations may see structural weakness going forward.
- Additionally, increased competition in the Asian phenolic market, due to the entry of global giant INEOS through Mitsui Chemicals' acquisition, may also lead to a glut if demand does not keep up pace with supply.

## Downstream products to lead next leg of volume growth

- Upcoming capacities of MIBK (40ktpa), MIBC (8ktpa) and Polycarbonate should drive volume growth going ahead. While we do not expect margin accretion since the products are commodities in nature, vertical integration may lead to some reduction in margin volatility.
- MIBK is primarily used as a solvent for resins used in the paints and coatings industry. It could be an ideal import substitution play, considering India's entire MIBK demand of ~30,000mtpa is exclusively met through imports.
- Polycarbonate is a transparent thermoplastic polymer widely used in the electrical/electronics industry due to its excellent heat and electrical resistance property. According to ChemAnalyst, India's Polycarbonate demand stood at 180,000mtpa in FY22 and is expected to grow by ~4% over the next decade, driven by the building and construction materials end market.

### Swarnendu Bhushan- Research Analyst (Swarnendu.Bhushan@MotilalOswal.com)

## Investors are advised to refer through important disclosures made at the last page of the Research Report.


Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Covestro, the world leader in Polycarbonate, expects a 4% CAGR in the global polycarbonate market till CY26, while the supply is expected to grow by 5-6% during the same period, led by major capacity additions in China by Hainan Huasheng, ZPC, SABIC-Sinopec, Wanhua and Shemna.

### **Valuation and View**

- The company aims to become the largest player in Solvents, with a play on import substitution. It has already announced its foray into MIBK (40ktpa), MIBC (8ktpa) and Polycarbonate.
- Despite a capex of INR20b over the next three years, DN is expected to turn net cash positive by FY24 with FCF generation of INR16.5b over FY23-25. Return ratios are expected to be at 24-27%, significantly lower than that of FY22.
- The company is on an aggressive path for backward as well as forward integration. However, the complete basket of products is commodity and the current valuation appears rich. We maintain our Neutral rating with a TP of INR1,890, valuing DN at 20x Dec'24E EPS of INR95.

### Exhibit 1: Phenol/Acetone spread over raw materials has remained flat at QoQ at INR90/kg during 4QFY23'td



Source: Indianpetrochem, MOFSL





Exhibit 2: Phenol prices have come down in 4QFY23'td v/s 3QFY23, while Acetone prices have increased during the same period

Source: Indianpetrochem, MOFSL

## MOTILAL OSWAL


#### Deepak Nitrite

#### Exhibit 3: DN's legacy products have been commodities



Source: Company, MOFSL

#### Exhibit 4: Upcoming phenol downstream products are also commodities in nature



# Exhibit 5: 52% of the total Phenol imports by the top 10 importing countries is done by China (as of CY20)

52%

as a % of top 10 importing countries

14%


5%

21%

8%

# Exhibit 6: India is the third largest importer of Polycarbonate in the world (as of CY21)





Source: WITS, MOFSL

China

India

Japan

Others

Netherlands


Source: WITS, MOFSL

Source: Company, MOFSL

Phenol

## MOTILAL OSWAL


## Exhibit 7: Expect a 4% CAGR in the global Polycarbonate market till CY26, while the supply is expected to grow by 5-6% during the same period



Source: Covestro, MOFSL



#### Exhibit 9: ...while Covestro, an international peer, trades at 8.5x one year forward P/E



Source: MOFSL


#### Exhibit 10: INEOS's acquisition of Mitsui Chemicals was also at modest valuation of 4.6x EV/EBITDA

EV/EDITDA		
Valuation metrics	CY21	Remarks
Acquired at	330	USD m
	26,235	INR m
Sales	750	USD m
	59,625	INR m
EBITDA	5,715	INR m
USD/ INR	80	as of 14th Sep'22
EBITDA Margin	10%	On Mitsui's Basic Materials division
EV/ EBITDA (x)	4.6	


Source: Mitsui Chemicals, MOFSL

## **Story in charts**


Exhibit 11: Revenue growth is expected to peak as product prices in DPL normalize going forward...




### Exhibit 13: Expect normalized EBIT margins to be at ~16-17%...



### Exhibit 15: : EBITDA margins to normalize from FY22 levels




#### Exhibit 17: DN to incur ~INR20b in capex over FY23-24E...




Source: Company, MOFSL


# Exhibit 12: ...resulting in a lower contribution from DPL in the total revenue mix








#### Exhibit 16: Expect ~7% PAT CAGR over FY23-25E



#### Exhibit 18: ...but is likely to turn net cash positive in FY24E



Source: Company, MOFSL

# **Financials and valuations**

Consolidated - Income Statement								(INR m)
Y/E March	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E	FY25E
Total Income from Operations	16,762	26,999	42,297	43,598	68,022	80,319	85,876	94,058
Change (%)	15.2	61.1	56.7	3.1	56.0	18.1	6.9	9.5
Gross Margin (%)	38.0	39.0	43.9	48.1	39.5	32.5	36.7	36.6
EBITDA	1,963	4,139	10,258	12,470	16,036	12,622	18,438	19,870
Margin (%)	11.7	15.3	24.3	28.6	23.6	15.7	21.5	21.1
Depreciation	526	778	1,397	1,526	1,777	1,675	2,378	2,574
EBIT	1,437	3,361	8,861	10,944	14,259	10,947	16,061	17,296
Int. and Finance Charges	451	832	1,149	742	340	277	293	297
Other Income	123	151	352	215	426	442	515	546
PBT bef. EO Exp.	1,109	2,680	8,064	10,417	14,345	11,112	16, <b>283</b>	17,545
EO Items	0	0	0	0	0	0	0	0
PBT after EO Exp.	1,109	2,680	8,064	10,417	14,345	11,112	16,283	17,545
Total Tax	318	943	1,954	2,659	3,678	2,833	4,098	4,416
Tax Rate (%)	28.7	35.2	24.2	25.5	25.6	25.5	25.2	25.2
Reported PAT	790	1,737	6,110	7,758	10,666	8,278	12,184	13,129
Adjusted PAT	790	1,737	6,110	7,758	10,666	8,278	12,184	13,129
Change (%)	72.4	119.8	251.9	27.0	37.5	-22.4	47.2	7.7
Margin (%)	4.7	6.4	14.4	17.8	15.7	10.3	14.2	14.0
Consolidated - Balance Sheet								(INR m)
Y/E March	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E	FY25E
Equity Share Capital	273	273	273	273	273	273	273	273
Total Reserves	8,949	10,443	15,446	23,194	33,112	40,148	50,505	61,664
Net Worth	9,221	10,716	15,719	23,467	33,384	40,421	50,778	61,937
Total Loans	9,866	12,286	10,279	5,775	3,007	3,909	1,954	977
Deferred Tax Liabilities	454	775	796	1,078	1,229	1,229	1,229	1,229
Capital Employed	19,541	23,776	26,794	30,320	37,620	45,558	<b>53,961</b>	64,143
Gross Block	6,403	17,749	20,460	22,441	25,263	32,763	40,263	45,263
Less: Accum. Deprn.	528	743	2,140	3,666	5,443	7,118	9,496	12,070
Net Fixed Assets	5,875	17,006	18,320	18,774	19,820	25,645	30,767	33,193
Capital WIP	9,545	339	1,723	2,068	1,037	1,037	1,037	1,037
Total Investments	318	24	24	1,893	4,390	4,390	4,390	4,390
Curr. Assets, Loans, and Adv.	10,167	11,910	12,019	12,868	19,057	23,001	26,383	34,992
Inventory	3,272	4,107	3,945	3,827	5,846	7,612	7,583	8,342
Account Receivables	4,118	5,750	6,127	7,563	11,291	13,332	14,254	15,612
Cash and Bank Balance	482	258	314	334	418	282	2,649	8,960
Cash	94	30	21	89	229	92	2,459	8,770
Bank Balance	388	228	293	245	189	189	189	189
Loans and Advances	2,296	1,795	1,633	1,144	1,503	1,775	1,897	2,078
Curr. Liability and Prov.	6,364	5,502	5,292	5,283	6,684	8,514	8,617	9,470
Account Payables	5,953	4,724	3,643	4,367	5,117	6,664	6,638	7,303
Other Current Liabilities	280	587	1,385	640	1,272	1,501	1,605	1,758
Provisions	132	191	264	276	296	349	373	409
Net Current Assets	3,803	6,408	6,727	7,585	12,373	14,487	17,766	25,522
Appl. of Funds	19,541	23,776	26,794	30,320	37,620	45,558	53,961	64,143

# **Financials and valuations**

Ratios								
Y/E March	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E	FY25E
Basic (INR)								
EPS	5.8	12.7	44.8	56.9	78.2	60.7	89.3	96.3
EPS Growth (%)	72%	120%	252%	27%	37%	-22%	47%	8%
Cash EPS	9.6	18.4	55.0	68.1	91.2	73.0	106.8	115.1
BV/Share	67.6	78.6	115.2	172.0	244.8	296.3	372.3	454.1
DPS	1.3	6.5	4.5	5.5	7.0	9.1	13.4	14.4
Payout (%)	27.0	61.6	12.1	9.7	9.0	15.0	15.0	15.0
Valuation (x)								
P/E	311.6	141.8	40.3	31.7	23.1	29.7	20.2	18.8
Cash P/E	187.1	97.9	32.8	26.5	19.8	24.7	16.9	15.7
P/BV	26.7	23.0	15.7	10.5	7.4	6.1	4.8	4.0
EV/Sales	15.2	9.6	6.1	5.8	3.7	3.1	2.9	2.5
EV/EBITDA	130.2	62.4	25.0	20.2	15.5	19.8	13.3	12.0
Dividend Yield (%)	0.1	0.4	0.2	0.3	0.4	0.5	0.7	0.8
FCF per share	-32.1	-13.3	25.6	57.8	46.8	3.5	47.2	70.0
Return Ratios (%)								
RoE	9.7	17.4	46.2	39.6	37.5	22.4	26.7	23.3
RoCE	6.5	10.5	27.6	29.1	32.1	20.4	24.9	22.6
RoIC	10.7	13.5	28.0	32.1	36.7	22.8	28.0	27.1
Working Capital Ratios								
Fixed Asset Turnover (x)	2.9	2.4	2.4	2.4	3.5	3.5	3.0	2.9
Asset Turnover (x)	0.9	1.1	1.6	1.4	1.8	1.8	1.6	1.5
Inventory (Days)	71	56	34	32	31	35	32	32
Debtor (Days)	90	78	53	63	61	61	61	61
Creditor (Days)	130	64	31	37	27	30	28	28
Leverage Ratio (x)								
Current Ratio	1.6	2.2	2.3	2.4	2.9	2.7	3.1	3.7
Interest Coverage Ratio	3.2	4.0	7.7	14.7	41.9	39.6	54.8	58.3
Net Debt/Equity ratio	1.0	1.1	0.6	0.2	0.1	0.1	0.0	-0.1
Consolidated - Cash Flow Statement								(INR m)
Y/E March	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E	FY25E
OP/(Loss) before Tax	1,109	2,680	8,064	10,417	14,345	11,112	16,283	17,545
Depreciation	528	778	1,397	1,526	1,777	1,675	2,378	2,574
Others	481	829	1,262	852	295	277	293	297
Direct Taxes Paid	-279	-561	-1,985	-2,365	-3,535	-2,833	-4,098	-4,416
(Inc.)/Dec. in WC	-9	-3,123	-1,092	-412	-4,643	-2,250	-913	-1,445
CF from Operations	1,830	603	7,647	10,019	8,239	7,980	13,942	14,554
(Inc.)/Dec. in FA	-6,206	-2,410	-4,160	-2,140	-1,862	-7,500	-7,500	-5,000
Free Cash Flow	-4,376	-1,808	3,487	7,879	6,377	480	6,442	9,554
Change in Investments	906	299	3	-1,854	-2,401	0	0	0
Others	53	486	-122	33	22	0	0	0
CF from Investments	-5,247	-1,626	-4,279	-3,961	-4,241	-7,500	-7,500	-5,000
Issue of Shares	1,463	0	0	0	0	0	0	0
Inc./(Dec.) in Debt	2,626	2,033	-1,088	-5,246	-2,812	902	-1,954	-977
Interest Paid	-450	-841	-1,134	-736	-320	-277	-293	-297
Dividend Paid	-188	-213	-1,060	-4	-750	-1,242	-1,828	-1,969
Others	2	-20	-94	-5	24	0	0	0
CF from Fin. Activity	3,453	958	-3,376	-5,990	-3,858	-616	-4,075	-3,243
Inc./Dec. in Cash	36	-64	-8	68	139	-136	2,366	6,311
Opening Balance	58	94	30	22	90	229	93	2,459
Closing Balance	94	30	22	90	229	93	2,459	8,771

NOTES

Explanation of Investment Rating					
Investment Rating	Expected return (over 12-month)				
BUY	>=15%				
SELL	< - 10%				
NEUTRAL	< - 10 % to 15%				
UNDER REVIEW	Rating may undergo a change				
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation				

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at

#### http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

A graph of daily closing prices of securities is available at <u>www.nseindia.com</u>, <u>www.bseindia.com</u>. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views. **Regional Disclosures (outside India)** 

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions. For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered brokerdealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /gualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

#### Specific Disclosures

23 February 2023

- MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- Research Analyst has not served as director/officer/employee in the subject company 6
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received any compensation or other benefits from third party in connection with the research report
- MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however, the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

## Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022-3980

4263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-71881085.

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL: IN-DP-16-2015; NSDL: IN-DP-NSDL-152-2000; Research Analyst: INH000000412. AMFI: ARN .: 146822. IRDA Corporate Agent - CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products. Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.